Drugmakers rely on ‘use codes’ to vastly expand the nature of their patent claims, STAT analysis shows

Taking stock of the drug industry, from the lab to the medicine chest

September 18, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Mike Reddy for STAT STAT+ | Inside the quiet strategy pharma giants are using to fend off generics and drive up the cost of medicines FDA Orange Book shows spike in use codes from 0.7 per drug in 2001 to 9.9 today. Analysts say the codes can hamper effort to bring new generic drugs to market. By Ed Silverman and Michael Nolan STAT+ | Roivant strikes another deal, selling dermatology spinoff to Organon in deal worth $1.2 billion CEO Matt Gline has been on a dealmaking spree over the last year, starting off with his sale of a drug to Roche for $7.1 billion upfront last year. By Allison DeAngelis Opinion: Tested in Africa, used in America We need a new mandate for global drug and vaccine development research in low- and middle-income settings. By Mark Siedner and Rochelle Walensky NIH/NCI Center for Cancer Research STAT+ | Biotech feud over the multibillion-dollar cancer blood test market spills onto social media Guardant Health co-CEO offers $1 million bet to Exact Sciences CEO that early results of new colon cancer test won't hold up in larger trial By Jonathan Wosen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser